Previous close | 157.54 |
Open | 157.80 |
Bid | 0.00 x 1100 |
Ask | 0.00 x 800 |
Day's range | 157.45 - 158.60 |
52-week range | 134.09 - 175.91 |
Volume | |
Avg. volume | 6,399,771 |
Market cap | 279.175B |
Beta (5Y monthly) | 0.59 |
PE ratio (TTM) | 23.87 |
EPS (TTM) | 6.63 |
Earnings date | 27 Apr 2023 - 01 May 2023 |
Forward dividend & yield | 5.92 (3.76%) |
Ex-dividend date | 13 Apr 2023 |
1y target est | 163.87 |
While there's no ironclad method for picking perfectly safe stocks, thankfully there are a few dividend-paying companies that are a bit less risky than average -- as a result of their history of effective competition and their management's skill at executing their business models. Both of the stocks I'll review in a moment are likely to keep growing and paying their shareholders for a very long time, and that means you aren't likely to regret making a purchase. When it comes to appealing biopharma dividend stocks that investors can depend on, AbbVie (NYSE: ABBV) is near the top of the list.
The Schwab U.S. Dividend ETF (NYSEMKT: SCHD) just went through its annual reconstitution, meaning the top positions look different than they did just a few weeks prior. AbbVie (NYSE: ABBV) is now the fund's largest weighted position.
In the latest trading session, AbbVie (ABBV) closed at $157.54, marking a -0.3% move from the previous day.